Last reviewed · How we verify

Hair-X Hair Loss Relief (SELENIUM)

Chattem · FDA-approved active Small molecule Quality 15/100

SELENIUM (Hair-X Hair Loss Relief) is a marketed product by Chattem designed to stimulate hair growth, though its exact mechanism remains unknown. The key composition patent is set to expire in 2028, providing a clear timeline for potential generic competition. The primary risk lies in the lack of specified primary indication and key trial results, which may limit its market differentiation and regulatory support.

At a glance

Generic nameSELENIUM
SponsorChattem
Drug classNon-Standardized Fungal Allergenic Extract [EPC]
ModalitySmall molecule
Therapeutic areaImmunology
PhaseFDA-approved
First approval1997

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: